- Rating
- 2
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 3
Read review
Paper summary
The paper presents DeMMO for estimating clinical scores from wearable-derived mobility measures across four diseases and five visits. It combines temporal smoothing, feature selection, and learned relations between disease–outcome models. On Mobilise-D, it reports modest but consistent improvements over eight baselines and uses stability selection to identify reliable mobility features.
Critical strengths
- The dataset is great. The study uses a valuable combination of four disease cohorts, repeated follow-up, and common mobility measures. This makes it possible to study which mobility patterns can be shared across diseases, a question that single-disease studies cannot answer.
2)The model is easy to inspect, and the evaluation keeps all visits from each participant in the same split. Its gains across most outcome–visit tasks provide encouraging evidence that the approach is useful.
Critical weaknesses
-
The methodological advance appears limited. Temporal smoothing and sparse feature selection follow cFSGL, while the parameter reconstruction term is close to AutoTR (Zhou and Yang, KDD 2023). Using complete longitudinal mappings as tasks is a reasonable extension, but the paper does not clearly establish a substantial advance in relation learning.
-
The experiments do not sufficiently isolate the benefit of cross-disease sharing. The comparison with cFSGL changes both sharing and regularization: even with A fixed to zero, the added relation term penalizes coefficient magnitude. Without controls for this effect and for within-disease sharing, the modest improvement is hard to attribute to the main proposed mechanism. These concerns lead me to lean toward weak reject.
Questions for authors
-
What technical capability does the relation-learning mechanism add beyond applying AutoTR-style parameter reconstruction to longitudinal disease–outcome mappings?
-
Under the same tuning protocol, how does DeMMO compare with cFSGL plus an L2 penalty, and with a version that allows sharing only within each disease? These comparisons would help establish the separate benefit of cross-disease sharing.
-
Does the visit-specific model outperform a model that shares the same coefficients across all visits? This would help show how much the temporal component contributes.